About Event
Capturing the industry’s most exciting developments to tackle rare & genetic kidney diseases
Returning for its 5th year, the Rare & Genetic Kidney Disease Drug Development Summit unites leading experts to tackle the industry's most pressing challenges. This includes deciphering complex mechanistic renal biology, advancing novel biomarkers, determining critical surrogate endpoints in clinical trials, and leveraging automation and electronic health records for precise measurement and outcomes.
With insights from 24+ expert speakers from Novartis, Regeneron, AstraZeneca, Purespring Therapeutics, Everest Medicines, Maze Therapeutics, and more, this summit is your comprehensive guide to defining your rare and genetic renal strategy for 2025 and beyond. Delve into the immense opportunity presented by the next generation of life-changing therapeutics set to transform the lives of renal patients.
Join us for interactive discussions on:
Evolving strategies for rare renal patient subgroup identification using electronic health records so create a positive patient experience with Novartis and Nationwide Children’s Hospital
Identifying and validating surrogate endpoints that correlate with long-term outcomes in rare diseases lacking natural history data with Tufts Medical Centre and Alport Syndrome Foundations
Discussing multi-omics strategies for translating identified genetic effectors into druggable targets for genetic renal diseases with the University of Michigan, Regeneron and Maze Therapeutics
Focussing on innovative solutions to enhance clinical trial matching such as centralized platforms, longitudinal databases and the emerging ‘hub and spoke’ models with Novartis, Astra Zeneca and NephCure
Who Will You Meet?
With 24+ world-class speakers and 80+ senior attendees, join the largest community of rare and genetic kidney disease drug development experts worldwide for the unique opportunity to deep dice into pipeline development progress, lessons learns and novel strategies to accelerate clinical progress in orphan kidney disease populations.
Attending Job Titles in 2024:
What your peers have to say?
"I’m excited to engage with leading experts to exchange ideas, foster collaborations, and drive innovation in therapeutics and biomarker discovery. So, we can advance care for patients with rare kidney diseases." Rohit Gaurav, Principal Scientist
"Rare renal disease is where it is happening in the therapeutic development landscape!" Srini Srinivas, Senior Medical Director, Renal Diseases & Evidence Generational Lead